| 1 |
34150608 | Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer. | 2021 |
1 |
| 2 |
33408886 | Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy. | 2020 Dec |
1 |
| 3 |
29728098 | The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial). | 2018 May 4 |
1 |
| 4 |
23450278 | Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. | 2013 Mar |
1 |
| 5 |
23831020 | Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells. | 2013 Aug 19 |
1 |
| 6 |
22270929 | Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. | 2012 Aug |
1 |
| 7 |
19741502 | Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. | 2009 Nov |
1 |
| 8 |
20198292 | [Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer]. | 2009 |
1 |